Radiation therapy is one of the most common treatment strategies for thorax malignancies. One of the considerable limitations of this therapy is its toxicity to normal tissue. The lung is the major dose-limiting organ for radiotherapy. That is because ionizing radiation produces reactive oxygen species that induce lesions, and not only is tumor tissue damaged, but overwhelming inflammatory lung damage can occur in the alveolar epithelium and capillary endothelium. This damage may result in radiation-induced pneumonitis and/or fibrosis. While describing the lung response to irradiation generally, the main focus of this review is on cytokines and their roles and functions within the individual stages. We discuss the relationship between radiation and cytokines and their direct and indirect effects on the formation and development of radiation injuries. Although this topic has been intensively studied and discussed for years, we still do not completely understand the roles of cytokines. Experimental data on cytokine involvement are fragmented across a large number of experimental studies; hence, the need for this review of the current knowledge. Cytokines are considered not only as molecular factors involved in the signaling network in pathological processes, but also for their diagnostic potential. A concentrated effort has been made to identify the significant immune system proteins showing positive correlation between serum levels and tissue damages. Elucidating the correlations between the extent and nature of radiation-induced pulmonary injuries and the levels of one or more key cytokines that initiate and control those damages may improve the efficacy of radiotherapy in cancer treatment and ultimately the well-being of patients.
INTRODUCTION: HOW DOES THE LUNG RESPOND TO IONIZING RADIATION?
The lung is an organ composed of more than 40 different types of cells. Individually, these cells would be considered relatively radioresistant, but the organ as a whole has little regenerative capacity, meaning it is intolerant to higher doses of radiation [1] . Alveolar epithelial cells (or pneumocytes) are irreplaceabe in their important role in lung homeostasis. The ends of the respiratory tree, the lung alveoli ( Fig. 1 ), are lined with two types of alveolar epithelial cells: type I (AECI), also known as pneumocytes type I; and alveolar epithelial cells type II (AECII), also known as pneumocytes type II. Type I pneumocytes cover 90-95% of the alveolus. AECI are squamous, extremely flattened epithelial cells that form a complete, thin lining. These flat cells are responsible for oxygen and carbon dioxide exchange between the airspace and the underlying capillaries and express protein transport that maintains fluid homeostasis. By contrast, AECII cover just 7% of the total alveolar surface. Pneumocytes type II are typical cuboidal granular cells. They contain lamellar bodies in their cytoplasm that synthesize and secrete such pulmonary surfactant and immunomodulatory molecules as products of complement system, cytokines, lysozymes, and surfactant proteins (SPs) SP-A and SP-D (C-type lectins) involved in host defense. AECII are responsible for epithelium repair. They serve as stem cells for type I cells and can repopulate type I after insult [2] [3] [4] [5] .
In addition to epithelial cells, the alveolar space is also occupied by alveolar macrophages. They constitute a long-lived resident population, established in the lung during development and constantly patrolling the lung microenvironment. These macrophages are essential for tissue homeostasis, early pathogen recognition, as well as initiation of the local immune response and resolution of inflammation. Even in a homeostatic condition within the tissue, alveolar macrophages retain high phagocytic activity, working to clear particulate antigens and dead epithelial cells from the airways [6] [7] [8] .
The functional subunit of the lung is the alveolar-capillary barrier (ACB), which is also the subunit most sensitive to the effects of ionizing radiation [9] . This barrier is formed ultrastructurally by AECI and the endothelial cells of capillaries and their basement membranes. Both endothelial and epithelial cells are flat and thus have large surface areas but minimal cytoplasm. They compose the ACB, with a thickness of just 0.3 μm [6] [7] [8] [9] [10] . Moreover, the formation of tight junctions between alveolar epithelial cells is mostly responsible for the ACB's resistance to the movement of proteins [11] .
The most numerous cell populations in the alveolar interstitium are resident fibroblasts. The fibroblast population makes up >95% of the interstitial cells. Resident fibroblasts descend from various precursors and position themselves beneath epithelial cells or are scattered through the interstitium between the epithelial and endothelial layers, but without directly contacting the vasculature. These cells are highly adaptable, continuously adjusting the support they provide to growth, injuries repair or regeneration, and capable of cytokine production. Under certain pathological circumstances, resident fibroblasts may be activated and transform into myofibroblasts, which constitute the key effector cell type in tissue fibrosis [12] [13] [14] .
As ionizing radiation passes through lung tissue, its energy has sufficient strength to directly cause double-strand breaks in DNA molecules, as well as to hydrolyze water and other molecules. This hydrolysis resolves into the generation of reactive radicals [reactive oxygen (ROS) and nitric oxide (NOS) species] and may lead to secondary interaction with DNA and other cellular components or the extracellular matrix [15] . Although most DNA damage is repaired, any incorrect reparation may lead to cellular defects and cell death over a much longer period of time and can initiate a robust immune response even before any significant tissue damages occur [16] .
Irradiation of normal lung by thoracic or whole-body irradiation damages resident cells in the tissue. Epithelial and endothelial cell deaths after exposure to radiation can occur within hours through an apoptotic pathway. Apoptosis has been identified experimentally in the lung parenchyma within hours after injury [17] . Furthermore, DNA damages involving radiation can induce DNA repair system sensors, such as DNA-dependent protein kinase (DNA-PK), an ataxia telangiectasia-mutated gene (ATM), and an ataxia telangiectasiarelated gene (ATR) [18] . Activation of these sensors resolves by initiating specific transcriptional factors, such as nuclear factor kappa-lightchain-enhancer of activated B cells (NF-κB) [19] , p53, and SP-1 [20] . Additionally, oxidative stress and free radicals can result from the actions of pro-inflammatory cytokines. Moreover, the radiation itself also triggers a non-specific, acute 'cytokine storm' that resolves within 24 h. Release of these cytokines and other protein products of activated transcription factors may play a major role in subsequent radiation-induced lung injuries [21] .
RADIATION-INDUCED PULMONARY INJURY
Ionizing radiation on lung tissue may constitute a continuous spectrum of sequential molecular events. Radiation-induced pulmonary injury (RIPI) may result when there are insufficient repair mechanisms in the irradiated pulmonary tissue, or low efficiency in repopulating to replace damaged and/or dead lung tissue. In 1968, Rubin and Casserat [22] published their original description of radiation pneumonitis in three main clinical phases. These are: (i) an early phase lasting up to the first month that is a latent period of pneumonitis, (ii) an acute (intermediate, exudative) period that occurs in the period between 1 and 6 months, and (iii) a late or chronic phase occurring after 6 months and termed 'radiation fibrosis'. The most critical phase for preventing and possible treatment of RIPI is the early, latent phase ( Fig. 2A) , also known as radiation pneumonitis associated with early response. This occurs 2-4 weeks post-irradiation. Although during this phase histological and physiological damages present in the lungs are not evident by light microscopy, the changes are obvious on the molecular and cellular levels. Ultrastructural damages, meanwhile, are evident only by electron microscopy [23] .
The first occurrences are observed on the pneumocytes types I and II and endothelial cells. Experimental data show that AECI react to ionizing radiation by swelling and necrosis, which resolve in basement membrane denudation. This effect has been observed in various experimental models (rat, mouse) and also in relation to different irradiation schedules (whole body and local thorax) [24] . Within hours after exposure, AECII release surfactant into the Fig. 1 . Structural scheme of an alveolus in the lung under physiological conditions. The lung alveoli consist of an epithelial layer and an extracellular matrix surrounded by capillaries. The major cells in the alveolar wall comprise pneumocytes Types I and II, and alveolar macrophages. The gas-exchanging region, the alveolar-capillary barrier, is formed by Type I alveolar epithelial cells and the endothelial cells of the capillaries, and consists of the basement membrane between these cells. The interstitium of the alveoli is occupied by resident fibroblasts and forms an extracellular matrix. alveolar space [25] , but the proportions of surfactant subtypes are altered by a combination of increased synthesis and decreased metabolism of the heavier subtypes, and surface activity of surfactant subtypes is impaired [26] . Ultrastructural change in AECII is characterized by a decreased number of lamellar bodies, while the remaining lamellar bodies become enlarged and irregular within 24 h after irradiation [27] [28] [29] . Also, an insult on endothelial cells occurs within days after irradiation. The cytoplasm of endothelial cells is hypertrophied and vacuolated. These changes resolve into increased microvascular permeability, and 1 week post-irradiation there becomes evident separation from the basement membrane, interstitial edema, swelling, and obstruction in numerous capillaries [30] .
There is strong evidence from experimental data that hypoxia can be one of the driving forces in initializing and perpetuating RIPI. In rats, moderate hypoxia was revealed at 6 weeks and severe hypoxia at 6 months after hemithorax irradiation (Fisher-344 rats, right lube, single-dose 28 Gy) [31] , but in a later study using the same model the occurrence of temporal tissue hypoxia was observed just 3 days after irradiation [32] . These dramatic biochemical and ultrastructural events occurring a short time after irradiation are The subunit most sensitive to ionizing radiation is the alveolar-capillary barrier (ACB). The cytoplasm of endothelial cells is hypertrophied and vacuolated, resulting in increased microvascular permeability. Ultrastructural interstitial edema can be found in the ACB complex. AECII has decreased the number of lamellar bodies and releases impaired surfactant inside the alveoli. AECI reacts by swelling and necrosis, which results in basement membrane denudation. (B)Acute phase of radiationinduced pulmonary injury (radiation pneumonitis). This phase is characterized mainly by an inflammatory process triggered by damage to lung parenchyma, epithelial cells, vascular endothelial cells, and stroma. It involves the induction of proinflammatory cytokines and chemokines that recruit immune cells in the lung tissue. Recruited peripheral neutrophils, monocytes differentiated into macrophages and the cytokines produced by different cell types are most responsible for the acute inflammation.
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subsequently amplified by the cellular and tissue system and immediately activate perpetual cascades of cytokines and various gene expressions that persist until the acute phase of radiation pneumonitis becomes apparent [33] [34] [35] .
When a single dose was applied in a single fraction of <7.5 Gy, the incidence of RIPI development was close to 0%, but that incidence rose to 50% in humans when the single fraction was applied at a dose of 9.3 Gy [36] . Variability of lung sensitivity to ionizing radiation in rodents strongly depends on the genetic background of the individual experimental strains and the pulmonary damages exhibited after irradiation [37] . Doses range from 10 to 15 Gy for murine experimental models. Many factors affect the risk for developing pathologic syndromes, including, among others, the method of applying radiation, the volume of the irradiated lung, the total dosage and frequency of irradiation, associated chemotherapy, the genetic and other background of the patient, age, presence of chronic obstructive pulmonary disease, and smoking history [38, 39] . When RIPI develops, two gradually distinct, well-defined syndromes result: at the beginning there is an acute syndrome that can be characterized as radiation pneumonitis, and later there occurs radiation fibrosis. As many as 43% of patients will display radiographic evidence of lung injury, and the RIPI incidence has been reported to range between 5% and 24% in patients that have undergone thoracic irradiation and/or chemoradiotherapy [39] .
Although the mechanisms underlying radiation-induced pulmonary toxicity remain uncertain, recently the view regarding the mechanisms involved has shifted from the classical paradigm of the target cell kill hypothesis from the 1970s [40] to a theory of orchestrated response [33] , starting with ROS generation, followed by various activations of signal transduction pathways inducing processes leading to replacement of damaged cells, influx of inflammatory cells from peripheral blood and cytokine production, and development of radiation complications [41] . Despite these improvements in understanding, RIPI causes significant morbidity and mortality in patients treated for tumors in the thoracic region. In the following section, we will summarize general information about radiation pneumonitis and radiation fibrosis, as well as provide an update of recently observed evidence from scientists bringing new insight into old paradigms and establishing a new viewpoint that brings us closer to successfully understanding the tangled skein of processes that this radiation induces.
RADIATION PNEUMONITIS
Radiation pneumonitis develops as an acute reaction within 4-12 weeks after irradiation of the thorax region. Characteristic manifestations of this phase include non-specific symptoms like fever, chest pain, dry cough, and mild dyspnea or even respiratory failure in severe cases [42, 43] .
The acute pneumonitic phase (Fig. 2B ) is characterized by recruitment of diverse immune cells into the alveolar space, thickening of the alveolar septa, and disruption of the integrity of pulmonary alveoli. Infiltration of myeloid and lymphoid cells initiates tissue reactions, resulting in lung inflammation and edema of alveolar interstitium and air spaces [43] . AECI undergo apoptosis or necrosis, thereby causing denudation of the basement membrane. Depletion of AECI is followed by hyperplasia of AECII. Accelerated proliferation of AECII also leads, however, to neglect of their primary function, which is to produce pulmonary surfactant. The lack of surfactant results in a loss of surface tension, followed by edema and atelectasis of lung tissue [44] . The edema increases vascular permeability, which causes leakage of plasma protein and fibrin-rich exudates into the alveolar spaces.
One of the reasons radiation pneumonitis remains a major doselimiting complication for patients is that no specific treatment exists for it. The current treatment strategy is still non-specific and symptomatic and includes steroids and corticosteroids, diuretics, and such other substances as hormones, enzymes and antioxidants. A promising step forward is being made by supplementing soy products before and after irradiation as protection against radiation toxicity in tissue. The anticancer agents, soy isoflavones are non-toxic dietary plant estrogens extracted from soybeans. Their potential as a biological/nutritional intervention to protect against radiationinduced pneumonitis [45] [46] [47] improves the efficiency of radiotherapy and decreases its toxicity, as has been demonstrated in research and in a controlled clinical trial [48] .
If these damages are so intensive that it is not possible to restore homeostasis by any repair mechanisms, then the integrity of the ACB breaks down to a point of no return and regeneration of parenchyma becomes inadequate. The subsequent processes in lung tissue will then lead to the promotion of radiation fibrosis.
RADIATION FIBROSIS
Radiation fibrosis occurs as the last, irreversible phase in excess of 6 months after irradiation. It stabilizes after 2 years. A characteristic manifestation of radiation fibrosis is an accumulation of fibroblasts and myofibroblasts, resolving in extensive production of collagen (mainly subtypes I and III), infiltration of inflammatory cells, and remodeling of the extracellular matrix followed by fibrosis of alveolar septs, which cause widespread obliteration of the residual alveoli.
Pulmonary fibrosis is characterized by an accumulation of extracellular matrix proteins that ultimately compromise the lung's ability to exchange oxygen. These extracellular matrix proteins are secreted by scar-forming myofibroblasts, which express markers of smooth muscle cells. Myofibroblasts arise from undifferentiated resident lung fibroblasts in response to profibrotic stimuli, including ionizing radiation, with lung fibroblasts differentiating into myofibroblasts and secreting extracellular matrix proteins that can contribute to fibrogenesis. Therefore, inhibiting radiation-induced myofibroblast differentiation may be an important therapeutic approach in preventing radiationinduced extracellular matrix accumulation and fibrosis [49, 50] . Moreover, myofibroblasts constitute the main source of collagen production. They can derive from various cell types: resident stromal fibroblasts [51] , fibrocytes from bone marrow [52] , and even from ACEII [23] . Ionizing radiation activates fibroblasts/myofibroblasts, and that results in dysregulated and exaggerated repair processes leading to fibrosis [53] . Epithelial-mesenchymal transition (EMT) is one of the processes responsible for lung fibrosis. This process is activated in reaction to irradiation, but also in other pulmonary pathogenesis resolving with fibrosis; it is involved, too, in embryonic development [54] and tumorigenesis [55] .
The key fibrogenic cytokine of the EMT program is transforming growth factor-β (TGF-β) along with its signaling pathway. The crucial role of this cytokine in epithelial-mesenchymal transition will be described below. This process is initiated by transdifferentiation of epithelial cells to activated myofibroblasts [53] . A central role of these cells undergoing EMT is synthesis and deposition of extracellular matrix proteins. The extracellular matrix is a mixture of proteins (collagens and elastin), glycoproteins, proteoglycans (fibronectin, laminin and tenascin), glycosaminoglycans (heparin and chondroitin) and hyaluronic acid [56] .
A recent paper by Balli et al. provides new insight into the molecular mechanism of radiation-induced pulmonary fibrosis. It was discovered that a transcriptional factor, Forkhead box M1 (Foxm1), critical for the EMT process is induced through direct activation of Snail1 transcription and increase in inflammatory mediator expressions. Based upon two experimental models, lung samples from patients with idiopathic pulmonary fibrosis and transgenic epiFoxm1 KO mice were confirmed to have increased activity of Foxm1 in AECII-enhanced, radiation-induced pulmonary fibrosis [57] .
A later study by Xiong et al. identified that regulatory T lymphocyte (Treg) depletion in C57Bl/6 mice decreased alveolar septal thickening and collagen deposition in lung tissues of mice exposed to irradiation, and significantly increased nuclear or cytoplasmic β-catenin expression in alveolar epithelium, and Treg depletion by anti-CD25 antibody led to high Pro-SPC expression (epithelial marker) and low N-cadherin expression (mesenchymal marker) [58] . Evidence of an important role of β-catenin during the EMT process has been confirmed also in bleomycin-induced lung fibrosis [59] , and primary fibroblast cultures have been derived from lung tissue from a patient with idiopathic pulmonary fibrosis [60] .
Pan et al. offer a new and interesting outlook in their study showing that ABT-263 could selectively kill senescent cells and could reverse pulmonary fibrosis even when it already had become persistent in mice after thoracic irradiation. This finding suggests that ABT-263, a specific Bcl-2/xl inhibitor and a newly identified drug, has the potential to be an effective treatment for pulmonary fibrosis [61] .
CYTOKINES
Cytokines are small molecules of proteins, peptides or glycoproteins, produced as soluble factors by a variety of distinct cells, including all cells of the immune system, as well as endothelial, epithelial and stromal cells [62] . Cytokines are involved in nearly every response to immunity, inflammation and infection stimuli. Their function is triggered in such processes as proliferation, chemotaxis, mediation of inflammatory responses, homeostasis, differentiation, elimination of pathogens, and cell death [63] . During the past three decades, identification and classification of cytokines has undergone multiple developments. Initially, cytokines were identified based on their biological activities and termed lymphokines, monokines, interleukins and chemokines and numbered by order of discovery [64] . Since then, cloning and recombinant strategies have led to better understanding of cytokine biology and identified individual cytokines' expression patterns. Most recently, a successful and complete sequencing of the human genome has discovered a huge library of previously unrecognized proteins, and this also affected cytokine identification [65] . New cytokine classification has been assigned, and cytokines are now grouped into (super)families based on comparing sequences of known genes with sequences of discovered genes while assuming that homologous proteins should have related functions. In addition to this genomic classification, cytokines may be grouped in accordance with their functional properties or by the cells that produce them. Most cytokines have more than one prominent property, however, and are produced by different cell sources. Cytokines nomenclature is comprehensively summarized in an overview written by Brocker et al. [66] .
Despite some 50 years of studies to identify cellular and molecular mechanisms of radiation-induced damages, the exact mechanisms have not been recognized and not all signaling molecules have been discovered. It nevertheless is known that cytokines play a very important role. There have been many findings describing the propensity for a variety of cytokines to affect particular processes of RIPI [67] . For that reason, cytokines are intensively studied as signaling molecules relevant to the RIPI mechanism and as possible biomarkers to identify risk of RIPI development. Newer cytokinebased therapies and intervention in their signaling pathways comprise one of the fields of research. The goal of this review is to interpret the most important cytokines that are involved during RIPI, the relative mechanisms of action and consequences for irradiated tissue, as well as new approaches in treatment strategies or therapies.
CYTOKINE RESPONSES TO RADIATION
The production of each cytokine is time-dependent in response to ionizing radiation. Although each cytokine has its own, characteristic profile, within 4-24 h after irradiation there often occurs a nonspecific acute reaction (so-called 'cytokine storming'), and that is followed by decrease to baseline levels within a period of 24 h to a few days [68] . Based on all available data, there are two major investigational approaches for RIPI. The first relates mainly to patients having had clinically relevant high doses of thoracic radiation. After partial irradiation of the thoracic region, persistent waves of increased cytokine expression have been described in the lung tissue. Animal models (mainly murine) were established in order to better approximate the patient's situation. Murine models have been subjected to a localized high dose in a single exposure, and it is widely accepted that a dose threshold of 12 Gy needs to be exceeded for pneumonitis to occur [69] . The second approach involves identifying risk of RIPI after total body irradiation (TBI). This approach is based on historical nuclear accidents, such as those at Chernobyl [70] or Tokai-mura [71] , where people were undesirably exposed to ionizing radiation, as well as possible incidents involving dirty bombs or similar devices. TBI irradiation is also a commonplace procedure indicated for patients with bone marrow transplantation for hematologic malignancy [72] . Even when exposing the lungs to a dose within the 'subthreshold' range, there have been reported cases of patients suffering RIPI [73] . The roles of cytokines in TBI and lung damages caused by irradiation.
Hundreds of studies are available today that may provide great insight into a wide spectrum of cytokine profile and peaking after whole-and partial-body irradiation in patients and animal models. Herein, murine models of whole-thorax or hemithorax irradiation nicely reproduce the pathogenesis of the human disease with respect to its time course and clinical symptoms. The use of preclinical in vivo models has helped substantially to advance our understanding of the molecular mechanisms and signaling molecules that participate in the pathogenesis of radiation-induced adverse late effects in the lung.
In a study by Zhang et al. [74] , for example, plasma concentrations of 32 cytokines were determined after TBI with dose 9 Gy in identical murine models. This publication reports five temporal patterns of circulating cytokine expression. Furthermore, Johnson et al. [75] assessed whether a TBI dose in the range 0.5-10 Gy is necessary for the development of lung pathological changes and reported the responses of 22 cytokines in early and late time intervals. Unfortunately, this study showed no correlation between the acute cytokine responses to radiation and the late elevations in cytokine expression and/or pathophysiologic changes, but mice in later time intervals did manifest an increased and prolonged response to microbial lipopolysaccharide. After whole-lung irradiation with a dose of 12 Gy, Ao et al. [76] profiled 22 cytokines from different sources (serum, lung tissue, and bronchoalveolar lavage) in various time intervals and for two types of radiation-sensitive murine strains (C57Bl/6 and C3H). An interesting aspect of this study is that it endeavored to find a positive correlation between serum and tissue levels. Its findings clearly demonstrate that thoracic radiation induced significant strain-dependent early expressions of certain cytokines, as well as the strength of the correlations between their levels in tissue and blood.
All studies dealing with this matter have been conducted while attempting to identify the potential value of cytokines, chemokines, and/or their combinations as biomarkers for the individual stages of RIPI. We must bear in mind that for a cytokine to be useful as a biomarker its level in plasma should have a positive correlation with ongoing processes in lung tissue after irradiation, because in actual practice only blood (not other tissue samples) can be repeatedly taken from patients for screening and thus used as a surrogate marker for tissue. This review summarizes studies dealing with cytokine profiling, identifies the main relevant cytokine molecules and their participation during the RIPI process, and considers their prognostic values, as reported in Tables 1-3 for mice, rats and cancer patients, respectively. Also, the most promising candidates are discussed individually.
INTERLEUKIN-6
Interleukin-6 (IL-6) is a multifunctional pleiotropic cytokine belonging to the IL-6 type family [77] . Its functions are to stimulate the growth and differentiation of B and T lymphocytes, which are key players during inflammation and immune responses, to drive leukocyte trafficking and activation, and to induce production of acutephase proteins by hepatocytes. IL-6 promotes T-cell proliferation, B-cell differentiation and survival, and plasma cell production of IgG, IgA and IgM. It is synthesized by a variety of cells in the lung parenchyma, including alveolar macrophages, lung fibroblasts, and type II pneumocytes [78] . It is also produced in the body by mononuclear phagocytes, both types of lymphocytes, keratinocytes, hepatocytes, and bone marrow cells [79] . IL-6 is also produced in response to the production of various other cytokines (IL-1, IL-17 and TNF-α). Its receptor consists of an IL-6-binding chain (IL-6Rα) and a signal-inducing component (gp130). IL-6R exists in membrane-bound and soluble forms. The gp130 is the signaltransducing protein necessary for involving intracellular signaling through Janus kinase (Jak) and leading to phosphorylation of transcription factors in the STAT family and such signaling pathways as MAPK and PI3K [80] .
The precise role of IL-6 in predicting radiation pneumonitis and therefore its value as a biomarker have been debated. There have been large numbers of both animal model and clinical studies. Chen et al. consider IL-6 to be an important and valuable biomarker in connection with radiation-induced pneumonitis [81] [82] [83] . Their results suggest significantly higher pretreatment levels of IL-6 in blood specimens of patients who subsequently developed radiation pneumonitis, and higher levels of IL-6 thus constitute a significant predictor factor. Also increased was IL-1α, the levels of which showed positive correlation with those of IL-6 (P = 0.001) [83] . Therefore, the profibrotic cytokines and chemokines were not reliably predictive of radiation pneumonitis [39, 83] . Similarly, in a study by Arpin et al., correlation was reported between the occurrence of radiation pneumonitis and serum levels of IL-6 and IL-10 in patients during radiotherapy [84] . A not very positive result of IL-6 research was found in patients with advanced non-small-cell lung carcinoma. In this case, correlations were also observed between tumor response and the plasma concentration of IL-6 and TGF-β1, but this study concluded that this cytokine was being produced by a tumor and thus that it may impair the prospective identification of patients at risk [85] .
INTERLEUKIN-1
Interleukin-1 (IL-1) is a member of the IL-1 superfamily of cytokines that are important regulators of innate and adaptive immunity, playing key roles in host defense against infection, inflammation, injury and stress [86] . IL-1 includes two subtypes: interleukin-1α (IL-1α) and interleukin-1β (IL-1β). Both are agonists and are expressed in multiple cell lines throughout the body, including in monocytes, macrophages, neutrophils, hepatocytes, and tissue macrophages. IL-1α is expressed in cytoplasm as a 31 kDa precursor form (pro-IL-1α) that is biologically active and capable of binding to IL-1R and activating cells [87] . Moreover, IL-1α and IL-1β are functionally antagonized by the IL-1 receptor antagonist (IL-1RA), a soluble factor that binds non-productively to IL-1 receptors. IL-1β is an inducible cytokine and is not generally expressed in healthy cells or tissue. This type, however, is rapidly induced in cells by activation of such pattern recognition receptors as toll-like receptors and by pathogen products or factors released by damaged cells, thus leading to intracellular accumulation of the protein [88, 89] .
Damages to the epithelium of the lung as a result of exposure to ionizing radiation lead to release of IL-1α from stressed and/or necrotic cells into the extracellular space. The release of IL-1α from necrotic cells is unique and it can be considered to function as a damage-associated molecular pattern (DAMP) under these circumstances or as an alarm by binding to IL-1R1 and rapidly initiating the production of chemokines and inflammatory cytokines [90, 91] .
Because the two forms of IL-1 almost completely overlap in function and both are recognized by the same receptor, their Luminex 6-plex Serum Serum IFN-γ was significantly increased 16 h after exposure to 8 Gy (non-specific effect of ionizing radiation).
Kao et al. Millipore beads Serum A significant, dose-dependent increase in expression of IL-6 and KC was seen at early (1-4 h) time points, followed by a return to baseline levels by 1 d. At 9 mo after RT, there appeared to be a dose-dependent increase in KC expression. The concentration of GM-CSF decreased significantly as early as 1 h after irradiation and increased at 3 and 7 d after RT in lung tissue. The level of TNF-α significantly increased 5 d after irradiation and reached a maximum at 9 d. No differences were detected in the production of IL-6. Significantly increased TNF-α in sera was observed on Day 5, and IL-6 production on Days 5, 7 and 9, compared with non-irradiated controls.
Fedoročko et al. [35]
IL-1β, IL-6,TNF-α, GRO1, RANTES C57BL/6J TBI 60 Co/8 Gy 1,6 and 24 h ELISA Plasma, lung tissue IL-6 and GRO1 was increased in plasma, with a peak attained at 6 h; sustained production was observed at least up to 24 h. RANTES remained unchanged after radiation exposure. IL-1β and TNF-α remained undetectable in the plasma of irradiated animals. In the lung, TNF-α remained undetectable; IL-1β, IL-6 and GRO1 were produced in the lung, and radiation significantly elevated IL-1β and GRO1 levels. Plasma: IL6 and KC changes after both whole-lung irradiation and TBI, with a dose-responsive increase. Expression ↑ 1 h, a maximum at 6 h after irradiation, and return to baseline at 24 h. Robust response in TBI. Lung: IL-1β: all doses ↑1 h (×3-4). Similar responses with TBI (×3-9). At 6 h ↑ after irradiation, only the doses 5 and 10 Gy to the whole lung; in both, the levels returned to baseline by 24 h. IL1R2: all doses ↑ at 1 h. At 6 h, ↑ only for 10 Gy (lung); returned to baseline at 24 h. More robust response in TBI (1 h). CCR1 and CXCR2 receptors all doses ↑ 1 h after whole-lung irradiation (×2.5-5). At 6 h only the higherdose (2.5 Gy) ↑ CXCR2; returned to baseline at 24 h. Tang et al. IL-4 and IL-13 was significantly increased as early as 2 w after irradiation; IL-13 was increased until 16 w. IFN-γ and IL-1β were not elevated in BAL fluid. IL-13 is a critical factor promoting radiation-induced pulmonary fibrosis.
Chung et al. Xiong et al. [157] IL-1α, IL-1β, IL-6, TGF-β1, IL-13, MIP-2, MIP-1, CXCL16, IL-12p40, Ltn, RANTES, IL-5, sTNFR-1 Serum Cytokine levels in the serum after irradiation using a 3.5-mm collimator: IL-12 (p40) and G-CSF were increased at 2 w, while all other cytokine levels (IL-2, IL-6, ILb-1b, IL-13, TNF-α, MIP-1α, GM-SCF, IL-17, IFN-γ, MCP-1, eotaxin, MIP-1b, IL-4, IL12p70, p40, IL-10, G-CSF and RANTES) were increased at 1 w compared with the control. IL-3 was increased at the late time point 12 w. IL-1α and IL-9 decreased at 12 w. IL-5, KC and TGF-β1 did not show significant changes. Cytokine levels in the serum after irradiation using a 2-mm collimator: G-CSF was increased at 2 w; IFN-γ and IL-2 levels were increased at 1 w; TGF-β1 and IL-9 increased at 6 w; the remainder of the cytokines did not show significant changes between any time points.
Hong et al. [164] TNF-α, TGF-β1 C57Bl/6 Thorax X-ray/15 Gy 2 and 10 d ELISA, RT-PCR Lung tissue mRNA expression and protein levels of TNF-α and TGF-β1 at 10 d after irradiation were significantly increased compared with control group.
Jang et al. Two peaks in TGF-β1 production in the BALF: at 7-14 and 120 d after the irradiation. Plasma TGF-β1 also displayed two peaks. The irradiation induced increased levels of IL-1β, TNF-α, IL-10 and IL-6 in plasma at 30 d.
Xue et al. [176] IL-1α, IL-1β, IL-6, TNFα, TGF-β
Thorax X-ray/10 Gy 12 and 24 w RT-PCR Lung tissue IL-6 had higher levels of mRNA expression in the C57-WT mice relative to the other three groups of mice. There was increased mRNA expression at 12 and 24 wks after irradiation in the C57-WT mice. The TNFα −/− mice showed higher IL-6 protein levels than in the controls, and a smaller relative increase following irradiation. TNF-α mRNA expression in the C57-WT, TNFR1
−/− and TNFR2 −/− mice increased following irradiation. TGF-β mRNA expression in the lung tissue showed an increase Zaidi et al. [177] following irradiation at all the time points for all the groups of mice. Lung tissue TNF-α, IL-1α and IL-6 was detectable in the lung tissue within the first hours after thoracic irradiation, and there were significant upregulations of TNF-α at 1 h (mRNA) and at 6 h (protein), and of IL-1α and IL-6 at 6 h (mRNA) and at 12 h (protein). During the stage of acute pneumonitis, there was production of TNF-α (the maximal value at 4 w), and of IL-1α and IL-6 (both of which peaked at 8 w).
TGF-β1
Rübe et al. [194] IL In lung tissue after 20 Gy radiation, expression of mRNA for IL-1α, IL-1β and TNF-α increased in a bimodal fashion with time, peaking at 1-2 and 5-6 mo. In BALF, only IL-1α and IL-1β were increased. Similar, but less marked, changes were seen in both lung tissues and BAL cells after 12 Gy irradiation.
Chiang et al. [195] TGF-β, TNF-α, IL-1α/β, IL-6 BALB/c Thorax X-ray/20 Gy 6 and 24 h RT-PCR, RNA assay
Lung tissue Irradiation (20 Gy) induced a significant increase in TNF-α, IL-6, IL-1α/β and TGF-β mRNA 6 h and 24 h after irradiation.
Chen et al. [196] TNF-α, IL-1α, IL-6 C57BL/6J Thorax X-ray/ RT -PCR Lung tissue Initial increases were at 1 h for TNF-α and at 6 h for IL-1α and IL-6 post irradiation, then expression of these pro-inflammatory cytokines returned to basal levels (48 h-2 w). During the pneumonic phase, TNF-α, IL-1α and IL-6 were significantly elevated and revealed their maximum at 8 w.
Rübe et al. The main cytokine genes expressed in response to radiation were IL-1β, IL-1α and TNF-α, in decreasing order. The maximum expression in lung tissue appeared at 3-4 mo, while the maximum expression in BALF appeared at 1-2 mo. Sublethal doses of irradiation (6 and 12 Gy) showed similar, but less marked, changes.
Hong et al. [199] TNF-α C57BL/6J Thorax X-ray/ RNA assay Lung tissue IL-1α was elevated (×2) at 2 w, returned to the normal baseline, then increased at 8-26 w. An immediate fall in TGF-β1, TGF-β3 directly after irradiation was followed by increases in both seen at 2 w (larger increase in TGF-β3). This was followed by a general decline in TGF-β3, while the TGF-β1 level was continuing to increase (×2) at 8 w. Both returned to baseline at 16 w, but increased at 26 w. IL-x = interleukin-x, TGF-β1, 2 and 3= transforming growth factor β1 2 and 3, PDGF = platelet-derived growth factor, TNF-α = tumor necrosis factor alpha, Ltn = lymphotaxin (XCL1), IFN-γ = interferon γ, IP-10 = interferon gamma-induced protein-10 (CXCL10), G-CSF = granulocyte colony-stimulating factor, GM-CSF = granulocyte-macrophage colony-stimulating factor, CTGF = connective tissue growth factor, SCF = stem cell factor, FGF-β = basic fibroblast growth factor, VEGF = vascular endothelial growth factor, MIP-1α and -1β = macrophage inflammatory protein 1α and 1β (CCL3 and CCL4), MIP-2 = macrophage inflammatory protein (CXCL2), KC = keratinocyte chemoattractant (CXCL1), MCP-1 = monocyte chemoattractant protein-1 (CCL2), MCP-5 = monocyte chemoattractant protein-5 (CCL12), RANTES = regulated on activation normal T cell expressed and secreted (CCL5), MIF = macrophage migration inhibitory factor, MIG = monokine induced by gamma interferon (CXCL9), SDF-1α = stromal cell-derived factor 1, GRO1 (CXCL1) = growth-regulated oncogene-1, TSLP = thymic stromal lymphopoietin, TCA-3 (CCL1) = TARC thymus and activation-regulated chemokine (CCL17), MDC = macrophage-derived chemokine (CCL22), BALF = bronchoalveolar lavage fluid, ELISA = enzyme-linked immune sorbent assay, IHC = immunohistochemistry, WB = western blotting, (RT-) PCR = (reverse transcription)-polymerase chain reaction, Gy = gray, d = days, w = weeks, mo = months, y = years. Analysis of the BALF showed an increase in TGF-β between 3 and 8 w, peaking at 3-6 w for hemithorax irradiation by dose 30 Gy. The kinetics for irradiation15 Gy-whole thorax was similar kinetics but to a lesser extent (ELISA). The upregulation of TGF-β expression was dissemble at interval 1-4 w after whole-lung irradiation.
Yi et al. [235] IL-x = interleukin-x, TGF-β1 = transforming growth factor β1, PDGF = platelet-derived growth factor, TNF-α = tumor necrosis factor-α, HGF = hepatocyte growth factor, CTGF = connective tissue growth factor, IFN-γ = interferon γ, IP-10 = interferon γ-induced protein-10 (CXCL10), KC = keratinocyte chemoattractant (CXCL1), MCP-1 = monocyte chemoattractant protein-1 (CCL2), RANTES = regulated on activation normal T cell expressed and secreted (CCL5), GRO1 (CXCL1) = growth-regulated oncogene-1, CCRT = computer controlled radiation therapy, SD = Sprague-Dawley rat, BALF = bronchoalveolar lavage fluid, ELISA = enzyme-linked immune sorbent assay, IHC = immunohistochemistry, WB = western blotting, (RT-) PCR = (reverse transcription)-polymerase chain reaction, Gy = gray, d = days, w = weeks, mo = months, y = years. Table 3 . Summary of published studies analyzing cytokine expressions and in cancer patients undergoing radiotherapy of thoracic region, including type of radiotherapy, total received dose, time intervals, methods and materials used for cytokine quantification after irradiation. Gkkika et al. The pre-RT TGF-β1 level was 10.7 ± 2.3 ng/ml and the mean during-RT TGFß1 level was 6.0 ± 0.7 ng/ml. Differences in TGFß1 levels were found at pre-RT and during-RT in patients according to genotypes for TGFß1, tPA, ACE DD, II and ID. The serum IL-6 and TGF-β1 ratios (serum levels at the time 4 w after commencement of RT/pre-RT) differed significantly, and a borderline significant difference was found between RP and no-RP groups. IL-6 and TGF-β1 serum levels after delivery of 40 Gy increased more strikingly for patients who experienced RP. The mean TGF-β1 level was significantly higher than in normal controls. At Week 4 of RT, the level of plasma TGF-β1 did not differ significantly from the pre-RT level. In univariate analysis and multivariate analysis, performance status, weight loss, radiation dose, and TGF-β1 ratio (during-RT/pre-RT level) were all significantly correlated with overall survival.
Zhao et al.
[249]
IL-6, IL-8, IL-10, IL-12(p40/p70), IL-1RA, TNF-α, sTNF-R1
NSCLC patients
CXRT 64 Gy (50-70) Before RT and then weekly for 8 w during RT ELISA Serum There was a significant weekly increase in IL-6 (average of 4.4% each week). IL-6 was the only cytokine, whose increase was associated with an increase in the mean severity of the five most severe symptoms (pain, fatigue, disturbed sleep, lack of appetite, sore throat). There were also significant weekly increases in sTNF-R1 and IL-10. Not detectable: IL-1RA, IL-8, IL-12 (p40/ p70) and TNF-α.
Wang et al.
[250]
Continued
Radiation pneumonitis and fibrosis and their cytokines profiles • 733 There was an increased serum TGFβ1 level at the end of radiation therapy in the serum. There was an ncreasing trend compared with values before the radiotherapy (no significance). There was a significant increase in the TGF-β1 level expression in sputum at the end of radiotherapy.
[251]
TGF-β1, TNF-α 120 advanced lung cancer patients CRT, 3D-CRT 60 Gy, (45-75) Before and post RT ELISA Plasma Levels of TGF-β1 and TNF-α were markedly increased after radiotherapy.
Xia et al. [252] IL-6, IL-10, TNF-α, TGF-β1 96 NSCLC patients 3D-CRT 66 Gy (46-72) Before, every 2 w until 6 w and then at 6 mo after RT ELISA Serum None of the baseline cytokine levels were significantly associated with the occurrence of radiation fibrosis. Chronological changes in serum IL-6 levels were found in patients with fibrosis during the first 2 w of 3D-CRT (not significant).
Mazeron et al. Patients had significantly higher levels of serum IL-6, IL-8, IL-18 and VEGF than controls. IL-1β, IL-6, IL-8 and IL-18 levels were significantly higher in the BALF from patients than in BALF from controls. IL-1β levels were significantly lower among the patients, VEGF was not significantly different.
Crohns et al. However, the during-RT TGFβ1 level was significantly higher in patients with RILT at PU, but not at UM. The pre-RT TGF-β1 level was not significantly different in patients with RILT compared with in those without RILT, but the during-RT TGF-β1 level was
Zhao et al. [255] significantly higher in patients with RILT than in those without RILT.
IL-1α, IL-6, IL-10, TNF-α, TGF-β1 34 lung cancer patients 3D-CRT ≥45 Gy Beginning, in the middle, at the end of RT and at 2 and 4 w after RT
ELISA Plasma
The patients who developed pneumonitis showed a higher level of pre-treatment TGF-β1 (but this was not significant). During radiation treatment, from the beginning of RT to the middle of RT, the RP group tended to show a decrease in the TGF-β1 level. The pre-treatment IL-6 level was higher in the non-RP group compared with in the RP group. The changes in the levels of IL-6 during the time course were similar whether patients developed RP or not. The IL-1α, IL-10 and TNF-α levels did not correlate with the risk of RP.
Kim et al. [256] TGF-β1 52 NSCLC patients 3D-CRT 60-70 Gy Before and at 3, 6 and 12 w of RT ELISA Plasma The plasma TGF-β1 levels in RT and RT+ berberine groups increased during treatment and reached a peak at 6 w. TGF-β1 levels in the RT group were significantly higher at Weeks 3, 6 and 12.
Liu et al. [257] TNF-α, IL-1β, IL-6, TGF-β1 52 NSCLC patients 3D-CRT 66 Gy, palliative 32 Gy
Pre RT, weekly during RT and 1, 3, 6 and 9 mo post-RT ELISA Plasma There were increased levels of IL-6 and TGF-β1 in patients suffering moderate and severe lung toxicities (no clear correlation). Cytokine plasma levels measured before and during RT did not correlate with RP incidence. In most patients, IL-6 and TGF-β1 plasma levels were already elevated before RT and were correlated significantly with the IL-6 and TGF-β1 production in corresponding tumor biopsies. Moreover, IL-6 and TGF-β1 plasma levels measured during follow-up were significantly associated with the individual tumor responses of these patients.
Rübe et al. No statistically significant difference at baseline was found between the two groups (RT/RT + rhubarb). During treatment, the levels of TGF-β1 were increasing in both groups, and all reached a peak at 6 w. The levels of TGF-β1 at 2, 4, 6 and 12 w in the RT group were all significantly higher. Compared with the baseline, IL-6 levels in the control group were significantly higher during the treatment and reached a peak at 2 w. TGF-β1and IL-6 levels in the RT + rhubarb group were significantly lower than those in the RT group.
Yu et al. [259] TGF-β1 26 NSCLC patients 3D-CRT 65.7 Gy (64.2-70.1)
Weekly during, and then 1, 3, 6, 12 and 24 mo after RT ELISA Plasma The TGF-β1 levels in patients with lung cancer pre-RT were significantly higher than those of the normal controls. No significant difference pre-RT, at 2 and 4 w during RT, or at the end of RT was found between patients with and without RIPI. The mean TGF-β1 ratios increased in patients with RILT and decreased slightly in patients without RILT during the course of RT.
[260]
IL-1, IL-6, TGF-β1 134 NSCLC patients RTOG protocol 60-66 Gy Before, weekly (by 10 Gy), follow-ups every 3 mo/y and then annually ELISA Serum The TNF-α level was elevated at the baseline in 24% of patients, IL-6 in 35% and IL-1 in 10%. It was found that 32% of patients with an initial 0 level of TNF-α became elevated for at least one reading during the RT. TNF-α in 50%, IL-6 in 59% and IL-1 in 80% of patients remained at 0 throughout treatment. IL-6 at 10 Gy was the only factor to Hartsell et al. [261] indicate any relationship with acute lung toxicity. 30 higher than 30% and a ratio of end-RT/ baseline TGF-β1 level higher than 1 had a significantly higher incidence of RP. Grade 2 or higher RP was developed in 27 patients. Patients with a TGF-β1 concentration during RT lower than baseline had a significantly higher incidence of RP than did patients with a mid-RT TGF-β1 levels that were higher normal.
Evans et al. [262] IL-1α, IL-6 31 lung cancer patients CXRT, RT 63 Gy Pre RT, weekly during RT, and 2 w, 4 w, 12 w and 3 mo post-RT ELISA Plasma Temporal changes in the circulating IL-1 and IL-6 trend toward a decrease in IL-1α during RT and increase in IL-6 after RT. There was a statistically significant correlation at 4 w after RT, 8 w after RT, and 6 mo after RT (clinically symptomatic radiation pneumonitis was manifested).
Chen et al. Anscher et al. [109] IL-x = interleukin-x, EGF =epidermal growth factor, G-CSF = granulocyte-colony stimulating factor, GM-CSF = granulocyte-macrophage colony-stimulating factor, FGF = fibroblast growth factors, VEGF = vascular endothelial growth factor, PDGF = platelet-derived growth factor, IFNγ = interferon γ, IP-10 = interferon gamma-induced protein 10 (CXCL10), MIP-1α and -β = macrophage inflammatory proteins 1-alpha and beta (CCL3 and CCL4), MIP-3α and -β = macrophage inflammatory proteins 3-alpha and beta (CCL20 and CCL19), MIP-2 = macrophage inflammatory protein 2 (CXCL2), MCP-1 and -3 = monocyte chemoattractant proteins 1 and 3 (CCL2 and CCL7), MDC = macrophage-derived chemokine (CCL22), TGF-α and -β = tumor necrosis factors alpha and beta, RT = radiotherapy, 3D-CRT = 3D conformal radiation therapy, IMRT = intensity-modulated radiotherapy, SBRT = stereotactic body radiotherapy, ChRT = chemoradiotherapy, CRT = conventional radiotherapy, CXRT = concurrent chemoradiation therapy, RILI = radiation-induced lung injury, RTOG = radiation therapy oncology group protocol, CCRT = neoadjuvant concurrent chemoradiation therapy, RIPI = radiation-induced pulmonary injuries, RP = radiation pneumonitis, RILT = radiation-induced pulmonary toxicity, NSCLC = non-small-cell lung cancer, ELISA = enzyme-linked immune sorbent assay, BALF = bronchoalveolar lavage fluid, Gy = gray, NM = not mentioned, d = days, w = weeks, mo = months, y = years.
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functions have been investigated jointly in connection with RIPI. The kinetics of gene expressions were detected after 5 Gy and 12.5 Gy thoracic irradiation on two murine models: the fibrosissensitive strain C57BL/6 and the resistant C3H/HeJ. Gene expression of IL-1α and IL-1β demonstrated time-and dose-dependent kinetics and strain differences. IL-1α expression was upregulated from Day 56 post-irradiation in C57Bl/6. In contrast, IL-1β was increased in C3H/HeJ only at Days 56 and 182. The authors of this study, Johnston et al. [92] , point out that an alternation of mRNA levels of IL-1α during the 'latent' phase may contribute to fibrosis in the fibrosis-prone strain. Because IL-1β was not observed to make such a contribution, it appeared that this protein may have a protective function. Moreover, as mentioned previously, a positive correlation between IL-1α and IL-6 has been shown in patients with higher risk of radiation pneumonitis [83] .
INTERLEUKIN-4 AND INTERLEUKIN-13
Both interleukin-4 (IL-4) and interleukin-13 (IL-13) are members of the IL-4 family. They share genetic and structural elements, biological functions, and receptor-binding properties. These two cytokines are associated with T helper type II (Th2) cell differentiation [93] . IL-4 is a multifunctional, pleiotropic cytokine and the crucial factor in Th2 response development. It is produced in cells of various types, including lymphocytes, macrophages and fibroblasts, as well as in epithelial and endothelial cells. Its actions are generally to promote establishment of the humoral response, it functions as a growth factor for mast cells, and it plays a major regulatory role in allergic responses [94] . In macrophages, IL-4 inhibits the secretion of inflammatory chemokines and cytokines TNF and IL-1β, impairs their ability to produce ROS and NOS intermediates, and blocks interferon-γ (IFN-γ)-stimulated expression of cellular adhesion molecules [95] . IL-13 is a pleiotropic cytokine that is also involved in stimulation of Th2 cells. IL-13 is suspected to be a more central mediator of allergic inflammation, as well as an important effector of gastrointestinal parasite expulsion, tumor cell growth, and intracellular parasitism. An important function of IL-13 was discovered within the process of tissue remodeling and fibrosis, but that function has not yet been fully defined [96] . IL-4 and IL-13 bind with high affinity to the receptor for IL-4 (IL-4R), which is widely expressed among various cell types, and both contribute to differentiation of lung fibroblasts into myofibroblasts, and collagen production [97] .
Gene expression of IL-4 increases in a time-dependent manner after thoracic irradiation in animal models. The highest concentration has been found in lung tissue at Day 84 after hemithorax irradiation by a dose of 20 Gy. Cellular sources of this protein were identified in infiltrated cells from the peribronchial and perivascular areas, as well as in cells located in the alveolar lumen and in the alveolar septs. Further, macrophages showed substantial IL-4 production. These results suggest a correlation between local IL-4 protein expression and the development of RIPI. Another interesting finding from this study is that the IL-4 mRNA gene expression levels and the IL-4 protein levels do not closely correlate in the late stages [98] .
The role of these cytokines in the development of radiation pneumonitis and radiation fibrosis is further elucidated by studies on deficient mice exposed to radiation. IL-13-deficient mice were shown to be resistant to the progression of radiation-induced fibrosis, and the plasma of wild-type animals contained a high concentration of soluble IL-13Rα2 decoy receptor. Although this study clearly demonstrated IL-13 to be a critical mediator of radiation-induced lung injury, it also suggested that delivery of an IL-13 neutralizing agent may have therapeutic efficacy [99] . Also, evidence clearly suggests the therapeutic potential of IL-4. Exogenous administration to lethally irradiated mice (C57BL6/J) increased the 30-day survival fraction with a dose high as 8.5 Gy. The mechanism of action is not direct involvement in reconstruction of hematopoietic and/or gastrointestinal system damages, but the function may be as an effective agent with potential to limit radiation-induced inflammation [100] .
IL-4 knockout mice have been shown to vary with respect to the effects seen in RIPI. It is noteworthy that development of radiation fibrosis is not prevented or delayed by loss of IL-4. Otherwise, IL-4 appears to be somewhat abrogated in the pneumonitic phase. Studies have demonstrated the development and maintenance of pulmonary macrophage accumulation in the lung as occurring under the command of IL-4. An IL-4 mechanism during inflammation that has been identified involves blocking of granulocyte recruitment while instructing macrophages to downregulate production of proinflammatory chemotactic factors and to drive accumulation of tissue macrophages through self-renewal [101] . These cells are known as alternatively activated macrophages, or M2 cells. Due to increased IL-4 production, macrophages accumulate in sufficient numbers and proliferate at the site of injury, while tending toward the M2 phenotype. Mice lacking IL-4 show the enhanced pro-inflammatory macrophage phenotypes in the lung in response to irradiation, as well as higher occurrence of infiltrating monocytes and their maturation into alveolar macrophages [102] .
TRANSFORMING GROWTH FACTOR Β
TGF-β is the prototypical cytokine and first characterized member of the TGF-β family, comprising more than 60 proteins in multicellular organisms. Three distinct subtypes, TGFβ1-β3, are known in humans and show a high degree of homology between various species. These proteins regulate a wide range of processes, including a multiplicity factor mediating embryonic development and cellular processes including cell cycle control, cell differentiation, apoptosis, cellular homeostasis, and wound healing.
TGF-β isoforms are produced in excess in most organs and are stored in inactive form. They are synthesized as gene products that include both the active cytokine and a latency-associated peptide (LAP). LAP is an endogenous inhibitor of TGF-β activity. This product is cleaved in the endoplasmic reticulum by the endoprotease furin [103] . TGF-β activity is regulated by two proteins, LAP and TGF-β binding protein (LTBP), forming a larger complex in the cytoplasm called the 'large latent complex' (LLC). It can be activated by various physico-chemical treatments or by proteases [104] . TGF-β signals activate the Smad proteins, which act as both transduction proteins and transcription factors and are able to regulate gene expression of various targets, including procollagen I and III [105] . Ionizing radiation is one of the exogenous factors that have been shown to induce TGFβ activation within an hour, even at doses as low as 0.1 Gy. In particular, ionizing radiation increases TGF-ß1 expression and also induces extracellular activation of the LLC by proteolytic cleavage in response to the production of ROS generated by radiation [106] .
Plasma values of TGF-β1 are often elevated during radiotherapy in patients who have developed radiation pneumonitis. The prognostic value of this cytokine in patients has been a subject of heated discussion. Multiple research works by Anscher et al. have indicated that the monitoring of serial plasma TGF-β1 levels in patients undergoing thoracic radiotherapy for lung cancer may be a reliable means of identifying patients who will develop symptomatic radiation pneumonitis [107] [108] [109] . Lending support to this assertion, the prognostic value of TGF-β1 and IL-6 in correlation with plasma levels in corresponding tumor biopsies from non-small-cell lung carcinoma patients was confirmed by Rube et al. [85] . Contradictorily, however, the results of this study also showed that neither their absolute nor any relative values of cytokine in plasma can identify patients at risk for radiation pneumonitis. One must note that the role of TGF-β1 on radiation-induced lung toxicity can be confounded by tumors, because circulating TGF-β1 levels may be produced by lung tumors. The dynamics of the plasma TGF-β1 could be a marker of radiationinduced lung toxicity as well as a marker of tumor response to treatment [110] .
Therefore, Haiping and his team hypothesized that early intervention in the signaling pathway of TGF-β may be a promising target in preventing radiation-induced pathologies. They constructed a recombinant adenoviral vector carrying soluble TGF-β type II receptor, because they assumed that this receptor negatively affects TGF-β production and function. Results obtained from in vitro cell transfection and mice treated with this vector in combination with partial-and whole-lung irradiation (9 Gy) confirmed their hypothesis. Overexpression of this receptor in vivo affected TGF-β concentration in serum and bronchoalveolar lavage fluid. Furthermore, two-time administration 1 week before and 1 week after irradiation is able to suppress the biphasic pattern of radiation-induced TGF-β production and has been shown to significantly reduce signs of pneumonitis in lung tissue [111] . This study clearly demonstrated the crucial role of cytokines and their signaling pathways in radiation-induced lung damages, and it progressed to a specific, gene-based therapy as a new tool for executing a feasible and more efficient treatment strategy for patients.
CHEMOKINES AND THEIR RECEPTORS
Chemokines comprise a large family of small proteins, mostly structurally related molecules. The initial discovery of the first chemokines (CXCL8, CCL2) had led to the conclusion that the pivotal role of chemokines is to induce leukocyte migration during inflammation. Since then, with the identification of all chemokine genes (human and mouse) and as other chemokines have been discovered and their functions described, our understanding of chemokines and their roles in the immune system have changed. Chemokines are grouped into two main functional subfamilies: inflammatory and homeostatic chemokines. Inflammatory chemokines control the recruitment of leukocytes in inflammation and tissue injury. Homeostatic chemokines, meanwhile, carry out such housekeeping functions as navigating leukocytes to and within secondary lymphoid organs as well as in the bone marrow and the thymus during hematopoiesis. Many of the chemokines have critical roles in homeostasis or, depending on circumstances, overlap both functional areas in an organism [112] , because some inflammatory chemokines may have homeostatic functions and some homeostatic chemokines may be upregulated under certain conditions of inflammation. These are known as dual-function chemokines. Homeostatic chemokines tend to be expressed in specific tissues or organs, whereas inflammatory chemokines can be produced by many cell types in multiple locations. In addition to affecting immune cell trafficking and homeostasis, they fulfil a wide range of functions in angiogenesis, wound healing, collagen production, and the proliferation of hematopoietic precursors [113, 114] . The system of nomenclature for chemokines is based on an arrangement of secondary structure between four conserved cysteine residues that form disulfide bonds on the N-terminus of the molecule. These groups are: (X)C, CC, CXC and CX3C. In zebra fish alone there exists a fifth group: C(X) [115] .
CCL2 (MCP-1)
CCL2, also known as monocyte chemoattractant protein-1 (MCP-1), is a member of the CC chemokine family and a potent chemotactic factor for monocytes. The function of this chemoattractant protein involves the regulation of migration and infiltration of monocytes, memory T lymphocytes, and natural killer cells [116] . The major sources of CCL2 are monocytes and tissue macrophages in the lung, followed by endothelial and epithelial cells, fibroblasts, and alveolar macrophages [117, 118] . In addition, it is synthesized by smooth muscle, mesangial cells, astrocytes, and microglia. The production occurs constitutively, but higher concentrations appear after induction by oxidative stress, cytokines, or growth factors. The major sources of CCL2 are nevertheless monocytes and macrophages in tissue [119] . This chemokine is the most potent profibrotic chemokine, facilitating fibrosis both directly and indirectly through binding to its cell-surface receptor, CCR2, on hematopoietic cells (predominantly monocytes) and fibroblasts [120] . Data recently confirmed by Osterholzer et al. clarifies that the CCL2/CCR2 pathway is responsible for the accumulation of non-resident cells (monocytes and non-resident macrophages) and development of pulmonary fibrosis in response to diphtheria toxininduced idiopathic pulmonary fibrosis [121] .
Moreover, MCP-1 falls into a category of cytokines that are activated within minutes to hours after irradiation. The peak concentration occurs at 3 h after exposure to ionizing radiation, and heightened concentration remains even 182 days later [122] .
Improvements have been made in estimating radiation-induced lung toxicity by developing a new model based on combinations of cytokine concentrations, dose volumes, and dosimetry parameters, as well as by considering variable patient factors. With the identification of additional factors that interact with the effect of dose on lung toxicities, it could be possible to distinguish those patients who demonstrate better tolerance for high-dose radiotherapy. Although this multivariable model unfortunately has limited clinical applicability, it has identified MCP-1 as a suitable predictive parameter. MCP-1 levels increased the dose-dependent effect on the risk of Radiation pneumonitis and fibrosis and their cytokines profiles • 743 RIPI formation, but the study did not describe the mechanisms by which this cytokine interacts with ionizing radiation. More interestingly, the prognostic usefulness of this cytokine was shown only from pretreatment plasma levels. Moreover, the same characteristics were demonstrated for cytokines IL-1α and IL-8 and for the soluble CD40 ligand. Surprisingly, this model did not identify TGF-β1 to be correlated with risk of RIPI, but the authors did suggest that this cytokine may be independent of the radiation dose-dependent mechanism [123] . A study by Siva et al. [21] , meanwhile, recorded a temporal change in plasma concentration in these patients. Each patient sample was tested for a panel of 22 cytokines, from which just 12 cytokines were detected as responding to radiotherapy and only 6 of these were also dependent upon treatment. In patients with a higher grade of pulmonary toxicity, there was significant reduction in the levels of MCP-1 and CXCL10 [also known as interferon gamma-induced protein 10 (IP-10)] at 1 h. Also, significantly different concentration levels of eotaxin (within the CC group of chemokines), IL-6, and tissue inhibitor of metalloproteinases-1 (TIMP-1) occurred at 24 h in patients with sustained pulmonary toxicity. In addition, cytokine levels were strongly and linearly correlated with the dose applied to the irradiated normal lung tissue.
CXCL8 (IL-8)
CXCL8, previously known as interleukin-8, belongs to the CXC family. It was originally identified as a neutrophil chemotactic factor and isolated from stimulated human mononuclear cells. It is produced by macrophages and other cell types, such as epithelial cells, airway smooth muscle cells, and endothelial cells in the lung. Moreover, CXCL8 production can be induced by inflammatory cytokines, such as IL-1 and TNF-α [124] . Functionally, it is one of the major mediators of inflammation, as well as a chemoattractant for trafficking of basophils, T lymphocytes, and neutrophils across the vascular wall. It has recently been demonstrated to have angiogenic activities, as it induces migration of endothelial cells, and also to be capable of inducing a loss of focal adhesion, followed by chemotaxis and chemokinesis of fibroblasts. CXCL8 also stimulates the endothelial permeability of endothelial cells, as well as adhesion and subsequent cell contraction, thereby facilitating leukocyte exit from the circulation [125] . Indeed, CXCL8 is an important mediator of pulmonary edema, a form of pathological permeability, after lung injury [126] . Surprisingly, even though the human and mouse genomes are remarkably similar, CXCL8 does not have a mouse counterpart. The chemokines Cxcl1 (KC), Cxcl2 (MIP-2) and Cxcl5 (LIX) are regarded as functional homologues of IL-8 in animal models. Cxcl15 (lungkine) is unique to mouse and does not exist in humans [127, 128] . Cxcl11, also termed keratinocyte chemoattractant (KC), has been analyzed as a functional homologue in animal models in relation to radiation exposure. Responding similarly after both whole-lung and whole-body irradiation, KC's expression has been shown to be dose-responsive at 1 h, to peak at 6 h after irradiation, and to return to baseline at 24 h [17] . Nevertheless, important differences existing between the mouse and the human in the chemokine ligand CXC family must be taken into account. Thus, one must be cautious in attempting to extrapolate the mouse data into human disease biology.
Analysis of IL-8 plasma level has been confirmed to have prognostic value among cancer patients who do or do not develop radiation-induced lung injury. Patients with lower levels of plasma IL-8 before radiation therapy might be at increased risk of developing toxicity. This analysis demonstrated a significant difference in the IL-8 levels between those patients who did or did not develop RIPI after radiation treatment. Another finding was a positive correlation with elevated levels of TGFβ1 in combination with IL-8 but not with TGFβ1 alone [129] . A similar conclusion was validated in papers by Wang et al. [130] and Stenmark et al. [131] . All these studies point to the importance of cytokine concentrations reached within the first 2 weeks of treatment and thus that they may afford the opportunity to individualize therapy for patients.
CONCLUDING REMARKS
Tolerance of lung tissue to ionizing radiation and subsequent development of radiation pneumonitis and fibrosis remain the main limiting factors for efficient radiotherapy. Cytokines undeniably play various roles in the whole process. Research into immunological regulation of inflammation has discovered that there are many different types of cytokines mediating the inflammatory response of immune cells to radiation. These include chemokines, inflammatory cytokines, and fibrotic cytokines. The mechanisms of action for the majority of proteins have already been described in animal models and humans. These insights into radiation response have enabled many investigators to introduce and advance new ideas on how to interrupt this complex procedure. A major step forward for patients would be to identify useful biomarkers. Great efforts have been made using animal studies to identify cytokines showing positive correlation between samples of blood, bronchoalveolar fluid, and lung tissue, because it is not practical to obtain all those samples from patients. Even after many years of research, however, prognostic values have been proven only for a few cytokines, including IL-6 and TFG-β1. In those cases, higher pretreatment levels are correlated with subsequent development of radiation pneumonitis. Hopefully, these findings will provide opportunity for individualizing treatments to improve therapeutic outcomes.
While one viewpoint links increased cytokine levels to pathogenesis, another is directed to using specific cytokine inhibitors in certain situations. The cytokines and their signaling pathways are useful targets for intervention. Through its intensive work in this field of research, the scientific community has made it possible to identify certain critical mediators in the context of lung tissue's response to radiation. IL-4 has been seen to be the most important cytokine in restoration and maintenance of pulmonary macrophage populations, which are critical mediators of chronic inflammation. On the other hand, the function of another cytokine from the same family, IL-13, appears to be important in the fibrotic phase. Neutralization of both cytokines by specific, monoclonal antibodies has resulted in improved RIPI. This approach may be among the most successful therapeutics in animal models, but it has not been approved for clinical use on patients. A humanized monoclonal antibody that selectively neutralized IL-13, tralokinumab, has already been tested with promising results for treating asthma and other inflammatory lung diseases [132] . Hopefully, further results will bring us to fully understanding the role of cytokines in radiationinduced disorders. The next step may lead to the development of specific cytokine-based therapies that will alleviate the limitations presently holding back efficient radiotherapy treatment.
